Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma.

Abstract

BACKGROUND\nTumor response and survival varies in patients treated with transarterial chemoembolization (TACE) for intermediate stage hepatocellular carcinoma (HCC) and may be associated with several factors.\n\n\nPURPOSE\nTo evaluate safety and efficacy of TACE in patients with intermediate stage HCC and to identify factors related to tumor response and survival.\n\n\nMATERIAL AND METHODS\nConsecutive patients with HCC treated with TACE between September 2008 and September 2018 were retrospectively reviewed.\n\n\nRESULTS\nIn 87 patients (71 men; mean age = 68\u2009±\u20099 years), 327 TACE treatments were performed (mean = 3/patient; range = 1-12). Mean and median overall survival were 32 and 19 months, respectively. Survival rates at 30 days, one, three, and five years were 99%, 71%, 19%, and 8%, respectively. Objective response (OR) was seen in 84% and disease control (DC) was seen in 92% of the patients. Patients in whom peritumoral portal lipiodol enhancement (PPLE) was seen during TACE had better OR (97 vs. 73%; P\u2009=\u20090.007) and DC (100 vs. 85%; P\u2009=\u20090.024), and a reduced risk of death (hazard ratio [HR] = 0.52; 95% confidence interval = 0.32-0.86) compared to those without PPLE. Severe adverse events were rare (15%) and occurred more often in patients with a larger tumor size.\n\n\nCONCLUSIONS\nTACE was effective and safe in patients with intermediate stage HCC. Patients with PPLE during TACE had better tumor response and longer survival than those without PPLE. Severe adverse events occurred more often in patients with larger tumors.